EMA Backs Insmed’s Brinsupri And Sanofi’s Wayrilz, Rejects Rezurock

 
• By Eliza Slawther
  
plaque psoriasis
Insmed’s Brinsupri and Sanofri’s Wayrilz are on track for pan-EU approval (Shutterstock)

More from EU CHMP

More from Product Reviews